OMNY Health debuts ophthalmology-centric real-world data platform
May 13th 2022The company is partnering with leading ophthalmology practices focused on improving patient outcomes. OMNY solutions are derived from electronic health record data and provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes.
Read More
AAO lauds Congress for passing key milestone for Prior Authorization Reform Bill
May 12th 2022The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.
Read More
Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Carr hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.
Read More
According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.
Read More
Patricia Bath, MD, inducted into the National Inventors Hall of Fame
May 5th 2022Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.
Read More
Study details formulation that offers enhanced IOP reduction
May 5th 2022In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.
Read More
WVU receives $11 million COBRE grant for visual sciences research center
May 5th 2022The grant, awarded by the National Institute of General Medical Sciences, a program of the NIH, will help West Virginia University investigators develop innovative ways to prevent, treat and slow the progression of vision problems that are currently incurable.
Read More
Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3
April 24th 2022David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.
Read More
ProQR announces additional sepofarsen Illuminate trial analyses
April 13th 2022According to the company, post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints. The company plans to discuss findings with regulators in Q3.
Read More
Editas Medicine doses first pediatric patient in clinical trial for LCA10
April 11th 2022The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.
Read More
Study examines high performance microscopy for non-invasive conjunctival goblet cell examination
April 8th 2022A team of investigators from Pohang University of Science and Technology has found that conjunctival goblet cell examination is important for the precise diagnosis and effective treatment of ocular surface diseases; however, CGC examination has not been possible until now due to lack of non-invasive devices.
Read More